Search results
Results from the WOW.Com Content Network
The study was a prospective, randomized, non-blinded trial for which the patients were randomized into two groups, (i) weekly INR self-testing and (ii) monthly INR clinic-testing, using a stratified method of adaptive-allocation that was determined according to the duration of anti-coagulation and the indication for Warfarin. Although the study ...
Warfarin is indicated for the prophylaxis and treatment of venous thrombosis and its extension, pulmonary embolism; [9] prophylaxis and treatment of thromboembolic complications associated with atrial fibrillation and/or cardiac valve replacement; [9] and reduction in the risk of death, recurrent myocardial infarction, and thromboembolic events such as stroke or systemic embolization after ...
8529 72054 Ensembl ENSG00000186115 ENSMUSG00000003484 UniProt P78329 Q99N16 RefSeq (mRNA) NM_001082 NM_024444 RefSeq (protein) NP_001073 NP_077764 Location (UCSC) Chr 19: 15.88 – 15.9 Mb Chr 8: 72.74 – 72.76 Mb PubMed search Wikidata View/Edit Human View/Edit Mouse Cytochrome P450 4F2 is a protein that in humans is encoded by the CYP4F2 gene. This protein is an enzyme, a type of protein ...
Vorapaxar is contraindicated for people with a history of stroke, transient ischemic attack, or intracerebral hemorrhage. [2] In studies of vorapaxar on persons with prior ischemic stroke, there was an increased risk of intracranial hemorrhage without an improvement in major vascular events.
The monitoring of warfarin and keeping the international normalized ratio (INR) between 2.0 and 3.0, along with avoiding over and under treatment, has driven a search for an alternative. [ 3 ] [ 14 ] A naturally occurring inhibitor of factor Xa was reported in 1971 by Spellman et al. from the dog hookworm. [ 15 ]
Warfarin treatment requires blood monitoring and dose adjustments regularly due to its narrow therapeutic window. If supervision isn't adequate warfarin poses a threat in causing, all too frequent, haemorrhagic events and multiple interactions with food and other drugs.
The higher incidence of major bleeding is thought to be the result of an approved dosing regimen that was too high, consequently the recommended dose was halved from the initial dose. [4] As of May 2012 Bayer HealthCare, the only manufacturer of lepirudin injections, discontinued its production. They expect supplies from wholesalers to be ...
An equianalgesic chart is a conversion chart that lists equivalent doses of analgesics (drugs used to relieve pain). Equianalgesic charts are used for calculation of an equivalent dose (a dose which would offer an equal amount of analgesia) between different analgesics. [1]